Combining oral anticoagulants with antiplatelet therapy in atrial fibrillation (AFib) patients could be more than just overkill, University of Edinburgh researchers reported at the European Society of Cardiology’s annual meeting this month. It could be dangerous, increasing the risk for all-cause death, stroke and major bleeding events in those without an indication for dual treatment.